Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a report issued on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

PIRS opened at $13.60 on Thursday. Pieris Pharmaceuticals has a one year low of $6.20 and a one year high of $22.32. The company has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. The business’s fifty day moving average is $15.65 and its two-hundred day moving average is $14.81.

Institutional Investors Weigh In On Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC bought a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals comprises approximately 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 40.11% of the stock is owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.